{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T07:18:22Z","timestamp":1697354302426},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,5,9]],"date-time":"2007-05-09T00:00:00Z","timestamp":1178668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1186\/1471-2261-7-14","type":"journal-article","created":{"date-parts":[[2007,5,10]],"date-time":"2007-05-10T02:13:20Z","timestamp":1178763200000},"source":"Crossref","is-referenced-by-count":6,"title":["Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study"],"prefix":"10.1186","volume":"7","author":[{"given":"Hari K","family":"Parthasarathy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khamis","family":"Alhashmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex D","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan D","family":"Struthers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John MC","family":"Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon T","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,9]]},"reference":[{"key":"14_CR1","doi-asserted-by":"crossref","unstructured":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama. 2002, 288: 2981-2997. 10.1001\/jama.288.23.2981.","DOI":"10.1001\/jama.288.23.2981"},{"key":"14_CR2","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/archinte.1981.00340130033011","volume":"141","author":"K Hiramatsu","year":"1981","unstructured":"Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T: A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981, 141: 1589-1593. 10.1001\/archinte.141.12.1589.","journal-title":"Arch Intern Med"},{"key":"14_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(94)93003-1","volume":"344","author":"RD Gordon","year":"1994","unstructured":"Gordon RD: Mineralocorticoid hypertension. Lancet. 1994, 344: 240-243. 10.1016\/S0140-6736(94)93003-1.","journal-title":"Lancet"},{"key":"14_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/sj.jhh.1001013","volume":"14","author":"PO Lim","year":"2000","unstructured":"Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM: High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens. 2000, 14: 311-315. 10.1038\/sj.jhh.1001013.","journal-title":"J Hum Hypertens"},{"key":"14_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(05)74868-6","volume":"353","author":"PO Lim","year":"1999","unstructured":"Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet. 1999, 353: 40-10.1016\/S0140-6736(05)74868-6.","journal-title":"Lancet"},{"key":"14_CR6","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1210\/jc.2001-012070","volume":"87","author":"PO Lim","year":"2002","unstructured":"Lim PO, Macdonald TM, Holloway C, Friel E, Anderson NH, Dow E, Jung RT, Davies E, Fraser R, Connell JM: Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. J Clin Endocrinol Metab. 2002, 87: 4398-4402. 10.1210\/jc.2001-012070.","journal-title":"J Clin Endocrinol Metab"},{"key":"14_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1161\/01.HYP.37.3.856","volume":"37","author":"PO Lim","year":"2001","unstructured":"Lim PO, Farquharson CA, Shiels P, Jung RT, Struthers AD, MacDonald TM: Adverse cardiac effects of salt with fludrocortisone in hypertension. Hypertension. 2001, 37: 856-861.","journal-title":"Hypertension"},{"key":"14_CR8","volume-title":"Incidence and workup of primary aldosteronism at the Mayo Clinic: ; Brisbane.","author":"W Young","year":"1999","unstructured":"Young W: Incidence and workup of primary aldosteronism at the Mayo Clinic: ; Brisbane. 1999."},{"key":"14_CR9","volume-title":"Incidence and workup of primary aldosteronism: Greenslopes Hospital series: ; Brisbane.","author":"R Gordon","year":"1999","unstructured":"Gordon R: Incidence and workup of primary aldosteronism: Greenslopes Hospital series: ; Brisbane. 1999."},{"key":"14_CR10","volume-title":"Outcomes of surgery for primary aldosteronism: an instituinal experience: ; Brisbane.","author":"AFC Van Heerden J A","year":"1999","unstructured":"Van Heerden J A AFC: Outcomes of surgery for primary aldosteronism: an instituinal experience: ; Brisbane. 1999."},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/bmj.2.5816.729","volume":"2","author":"JJ Brown","year":"1972","unstructured":"Brown JJ, Davies DL, Ferriss JB, Fraser R, Haywood E, Lever AF, Robertson JI: Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br Med J. 1972, 2: 729-734.","journal-title":"Br Med J"},{"key":"14_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7326\/0003-4819-131-2-199907200-00005","volume":"131","author":"RP Ghose","year":"1999","unstructured":"Ghose RP, Hall PM, Bravo EL: Medical management of aldosterone-producing adenomas. Ann Intern Med. 1999, 131: 105-108.","journal-title":"Ann Intern Med"},{"key":"14_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","volume":"19","author":"PO Lim","year":"2001","unstructured":"Lim PO, Young WF, MacDonald TM: A review of the medical treatment of primary aldosteronism. J Hypertens. 2001, 19: 353-361. 10.1097\/00004872-200103000-00001.","journal-title":"J Hypertens"},{"key":"14_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/archinte.1972.03650060047008","volume":"130","author":"EV Adlin","year":"1972","unstructured":"Adlin EV, Marks AD, Channick BJ: Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity. Arch Intern Med. 1972, 130: 855-858. 10.1001\/archinte.130.6.855.","journal-title":"Arch Intern Med"},{"key":"14_CR15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1001\/archinte.1967.04410010050007","volume":"120","author":"G Gwinup","year":"1967","unstructured":"Gwinup G, Steinberg T: Differential response to thiazides and spironolactone in primary aldosteronism. Arch Intern Med. 1967, 120: 436-443. 10.1001\/archinte.120.4.436.","journal-title":"Arch Intern Med"},{"key":"14_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","volume":"48","author":"PO Lim","year":"1999","unstructured":"Lim PO, Jung RT, MacDonald TM: Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol. 1999, 48: 756-760. 10.1046\/j.1365-2125.1999.00070.x.","journal-title":"Br J Clin Pharmacol"},{"key":"14_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","volume":"37","author":"BJ Gallay","year":"2001","unstructured":"Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC: Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001, 37: 699-705.","journal-title":"Am J Kidney Dis"},{"key":"14_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/bmj.322.7285.531","volume":"322","author":"E O'Brien","year":"2001","unstructured":"O'Brien E, Waeber B, Parati G, Staessen J, Myers MG: Blood pressure measuring devices: recommendations of the European Society of Hypertension. Bmj. 2001, 322: 531-536. 10.1136\/bmj.322.7285.531.","journal-title":"Bmj"},{"key":"14_CR19","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1161\/01.CIR.101.9.948","volume":"101","author":"JA Suwaidi","year":"2000","unstructured":"Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000, 101: 948-954.","journal-title":"Circulation"},{"key":"14_CR20","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1053\/euhj.1998.1094","volume":"19","author":"H Elming","year":"1998","unstructured":"Elming H, Holm E, Jun L, Torp-Pedersen C, Kober L, Kircshoff M, Malik M, Camm J: The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J. 1998, 19: 1391-1400. 10.1053\/euhj.1998.1094.","journal-title":"Eur Heart J"},{"key":"14_CR21","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1161\/01.CIR.98.15.1510","volume":"98","author":"J Nolan","year":"1998","unstructured":"Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Neilson JM, Fox KA: Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation. 1998, 98: 1510-1516.","journal-title":"Circulation"},{"key":"14_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999, 341: 709-717. 10.1056\/NEJM199909023411001.","journal-title":"N Engl J Med"},{"key":"14_CR23","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/S0735-1097(01)01243-8","volume":"37","author":"KM Yee","year":"2001","unstructured":"Yee KM, Pringle SD, Struthers AD: Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001, 37: 1800-1807. 10.1016\/S0735-1097(01)01243-8.","journal-title":"J Am Coll Cardiol"},{"key":"14_CR24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000, 101: 594-597.","journal-title":"Circulation"},{"key":"14_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/sj.jhh.1001138","volume":"15","author":"PO Lim","year":"2001","unstructured":"Lim PO, Donnan PT, MacDonald TM: Aldosterone to renin ratio as a determinant of exercise blood pressure response in hypertensive patients. J Hum Hypertens. 2001, 15: 119-123. 10.1038\/sj.jhh.1001138.","journal-title":"J Hum Hypertens"},{"key":"14_CR26","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000, 102: 2700-2706.","journal-title":"Circulation"},{"key":"14_CR27","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1097\/01.ASN.0000070142.14843.8E","volume":"14","author":"JM Flack","year":"2003","unstructured":"Flack JM, Peters R, Shafi T, Alrefai H, Nasser SA, Crook E: Prevention of hypertension and its complications: theoretical basis and guidelines for treatment. J Am Soc Nephrol. 2003, 14: S92-8. 10.1097\/01.ASN.0000070142.14843.8E.","journal-title":"J Am Soc Nephrol"},{"key":"14_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3810\/pgm.1996.10.94","volume":"100","author":"S Gandhi","year":"1996","unstructured":"Gandhi S, Santiesteban H: Resistant hypertension. Suggestions for dealing with the problem. Postgrad Med. 1996, 100: 97-102, 107-8.","journal-title":"Postgrad Med"},{"key":"14_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","volume":"21","author":"RD Gordon","year":"1994","unstructured":"Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994, 21: 315-318.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"14_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/00004872-198604000-00003","volume":"4","author":"CG Isles","year":"1986","unstructured":"Isles CG, Walker LM, Beevers GD, Brown I, Cameron HL, Clarke J, Hawthorne V, Hole D, Lever AF, Robertson JW: Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens. 1986, 4: 141-156. 10.1097\/00004872-198604000-00003.","journal-title":"J Hypertens"},{"key":"14_CR31","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1067\/mhj.2002.129969","volume":"144","author":"AD Struthers","year":"2002","unstructured":"Struthers AD: Aldosterone: cardiovascular assault. Am Heart J. 2002, 144: S2-7. 10.1067\/mhj.2002.129969.","journal-title":"Am Heart J"},{"key":"14_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","volume":"25","author":"CG Brilla","year":"1993","unstructured":"Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993, 25: 563-575. 10.1006\/jmcc.1993.1066.","journal-title":"J Mol Cell Cardiol"},{"key":"14_CR33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S0895-7061(99)00066-7","volume":"12","author":"A Sato","year":"1999","unstructured":"Sato A, Funder JW, Saruta T: Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens. 1999, 12: 867-873. 10.1016\/S0895-7061(99)00066-7.","journal-title":"Am J Hypertens"},{"key":"14_CR34","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003, 348: 1309-1321. 10.1056\/NEJMoa030207.","journal-title":"N Engl J Med"},{"key":"14_CR35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1042\/cs1030425","volume":"103","author":"CA Farquharson","year":"2002","unstructured":"Farquharson CA, Struthers AD: Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond). 2002, 103: 425-431.","journal-title":"Clin Sci (Lond)"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2261-7-14\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-7-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-7-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-7-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T19:18:28Z","timestamp":1548098308000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/1471-2261-7-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["14"],"URL":"https:\/\/doi.org\/10.1186\/1471-2261-7-14","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,9]]},"article-number":"14"}}